Rimegepant - Biohaven Pharmaceutical Holding Company

Drug Profile

Rimegepant - Biohaven Pharmaceutical Holding Company

Alternative Names: BHV-3000; BMS-927711; Rimegepant sulfate

Latest Information Update: 24 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Biohaven Pharmaceutical Holding Company; Bristol-Myers Squibb
  • Class 2 ring heterocyclic compounds; Antimigraines; Cycloheptanes; Small molecules
  • Mechanism of Action Calcitonin gene-related peptide receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Migraine

Most Recent Events

  • 28 Jun 2018 Biohaven Pharmaceutical Holding Company plans a phase III trial in Migraine (Prevention) by the fourth quarter of 2018
  • 22 Apr 2018 Updated efficacy data from two phase III trials in Migraine released by Biohaven Pharmaceuticals Holding Company
  • 26 Mar 2018 Adverse events and efficacy data from two phase III trials in Migraine released by Biohaven Pharmaceutical Holding Company
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top